Clinical Trial

Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma

Study acronym: CEVOLUTION
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess the efficacy and safety of cevostamab in combination with pomalidomide and dexamethasone (CevosPd) versus standard of care (SOC) in participants with multiple myeloma (MM) who have received one to three prior lines of therapy and have been exposed to an anti-CD38 monoclonal antibody (mAb) and lenalidomide.
Protocol Amendment History 6 changes
notable Trial sites expanded: 7 -> 15 locations 2026-07-21
notable Trial sites expanded: 4 -> 7 locations 2026-06-24
critical Recruitment opened 2026-05-28
notable Trial sites expanded: 0 -> 4 locations 2026-05-28
notable Primary completion moved earlier: 2029-06-29 -> 2028-10-31 2026-05-28
minor Completion pushed: 2032-12-31 -> 2033-01-31 2026-05-28
Trial Details
NCT Number NCT07555938
Lead Sponsor Hoffmann-La Roche
Conditions Multiple Myeloma
Enrollment 380 participants
Start Date 2026-06-23
Primary Completion 2028-10-31 (estimated)
Study Completion 2033-01-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-20